HLAVÁČEK, Antonín, Zdeněk FARKA, Matthias Jürgen MICKERT, Uliana KOSTIV, Julian BRANDMEIER, Daniel HORÁK, Petr SKLÁDAL, František FORET and Hans-Heiner GORRIS. Bioconjugates of photon-upconversion nanoparticles for cancer biomarker detection and imaging. Nature Protocols. Springer Nature, 2022, vol. 17, April 2022, p. 1028-1072, 47 pp. ISSN 1754-2189. Available from: https://dx.doi.org/10.1038/s41596-021-00670-7.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Bioconjugates of photon-upconversion nanoparticles for cancer biomarker detection and imaging
Authors HLAVÁČEK, Antonín (203 Czech Republic), Zdeněk FARKA (203 Czech Republic, guarantor, belonging to the institution), Matthias Jürgen MICKERT (276 Germany), Uliana KOSTIV (804 Ukraine), Julian BRANDMEIER (276 Germany, belonging to the institution), Daniel HORÁK, Petr SKLÁDAL (203 Czech Republic, belonging to the institution), František FORET (203 Czech Republic) and Hans-Heiner GORRIS (276 Germany, belonging to the institution).
Edition Nature Protocols, Springer Nature, 2022, 1754-2189.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10406 Analytical chemistry
Country of publisher Germany
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 14.800
RIV identification code RIV/00216224:14310/22:00119663
Organization unit Faculty of Science
Doi http://dx.doi.org/10.1038/s41596-021-00670-7
UT WoS 000757750800001
Keywords in English Photon-upconversion nanoparticle; Immunoassay; Immunocytochemistry; Cancer biomarker; Bioconjugation
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Marie Šípková, DiS., učo 437722. Changed: 14/4/2022 16:15.
Abstract
The detection of cancer biomarkers in histological samples and blood is of paramount importance for clinical diagnosis. Current methods are limited in terms of sensitivity, hindering early detection of disease. We have overcome the shortcomings of currently available staining and fluorescence labeling methods by taking an integrative approach to establish photon-upconversion nanoparticles (UCNP) as a powerful platform for cancer detection. These nanoparticles are readily synthesized in different sizes to yield efficient and tunable short-wavelength light emission under near-infrared excitation, which eliminates optical background interference of the specimen. Here we present a protocol for the synthesis of UCNPs by high-temperature co-precipitation or seed-mediated growth by thermal decomposition, surface modification by silica or poly(ethylene glycol) that renders the particles resistant to nonspecific binding, and the conjugation of streptavidin or antibodies for biological detection. To detect blood-based biomarkers, we present an upconversion-linked immunosorbent assay for the analog and digital detection of the cancer marker prostate-specific antigen. When applied to immunocytochemistry analysis, UCNPs enable the detection of the breast cancer marker human epidermal growth factor receptor 2 with a signal-to-background ratio 50-fold higher than conventional fluorescent labels. UCNP synthesis takes 4.5 d, the preparation of the antibody–silica–UCNP conjugate takes 3 d, the streptavidin–poly(ethylene glycol)–UCNP conjugate takes 2–3 weeks, upconversion-linked immunosorbent assay takes 2–4 d and immunocytochemistry takes 8–10 h. The procedures can be performed after standard laboratory training in nanomaterials research.
Links
GA21-03156S, research and development projectName: Foton-upkonverzní značky pro mikrofluidní jednomolekulové imunostanovení proteinových biomarkerů
Investor: Czech Science Foundation
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
LTAB19011, research and development projectName: Luminiscenční imunostanovení jako citlivý nástroj pro diagnostiku nemocí včel
Investor: Ministry of Education, Youth and Sports of the CR, Sensitive bioanalytical tools for the surveillance of honey bee diseases, INTER-ACTION
PrintDisplayed: 29/5/2024 17:13